Literature DB >> 12802748

Ceftriaxone compared with sodium penicillin g for treatment of severe leptospirosis.

Thanachai Panaphut1, Somnuek Domrongkitchaiporn, Asda Vibhagool, Bandit Thinkamrop, Wattanachai Susaengrat.   

Abstract

A prospective, open-label, randomized trial at Khon Kaen Hospital (Thailand) was conducted from July 2000 through December 2001 to compare the clinical efficacies of ceftriaxone and sodium penicillin G for the treatment of severe leptospirosis. A total of 173 patients with severe leptospirosis were randomly assigned to be treated with either intravenous ceftriaxone (1 g daily for 7 days; n=87) or intravenous sodium penicillin G (1.5 million U every 6 h for 7 days; n=86). The primary outcome was time to fever resolution. Survival analysis demonstrated that the median duration of fever was 3 days for both groups. Ten patients (5 in each group) died of leptospirosis infection. There were no statistically significant differences in the duration of organ dysfunction. Ceftriaxone and sodium penicillin G were equally effective for the treatment of severe leptospirosis. Once-daily administration and the extended spectrum of ceftriaxone against bacteria provide additional benefits over intravenous penicillin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802748     DOI: 10.1086/375226

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

1.  In vitro and in vivo activity of first generation cephalosporins against Leptospira.

Authors:  Brande M Harris; Peter J Blatz; Mary K Hinkle; Suzanne McCall; Miriam L Beckius; Katrin Mende; Janelle L Robertson; Matthew E Griffith; Clinton K Murray; Duane R Hospenthal
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

2.  In vitro sensitivity and resistance of 46 Leptospira strains isolated from rats in the Philippines to 14 antimicrobial agents.

Authors:  Antara Chakraborty; Satoshi Miyahara; Sharon Y A M Villanueva; Nina G Gloriani; Shin-Ichi Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

3.  Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.

Authors:  James E Moon; Michael W Ellis; Michael C Ellis; Matthew E Griffith; Joshua S Hawley; Robert G Rivard; Suzanne McCall; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  The kidney in leptospirosis.

Authors:  Regina C R M Abdulkader; Marcos Vinicius Silva
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

5.  Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.

Authors:  Roseanne A Ressner; Matthew E Griffith; Miriam L Beckius; Guillermo Pimentel; R Scott Miller; Katrin Mende; Susan L Fraser; Renee L Galloway; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

6.  Leptospirosis: pulmonary hemorrhage in a returned traveller.

Authors:  Victor Leung; Me-Linh Luong; Michael Libman
Journal:  CMAJ       Date:  2011-01-24       Impact factor: 8.262

7.  Spiraling Out of Control.

Authors:  Sara Mixter; Reza Sedighi Manesh; Sara C Keller; Laura Platt; Harry Hollander
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

8.  Bat-associated leptospirosis.

Authors:  Neelam A Vashi; Pavani Reddy; Diane B Wayne; Bradley Sabin
Journal:  J Gen Intern Med       Date:  2009-12-09       Impact factor: 5.128

9.  Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by a broth microdilution technique.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Broth microdilution susceptibility testing for Leptospira spp.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.